XenoPort (XNPT) Tops Q4 EPS by 10c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
XenoPort Reports Fourth Quarter and Year-End 2015 Financial Results
February 25, 2016 4:05 PM ESTFull-year 2015 net product sales of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets increased 96% to $39.5 million Total HORIZANT prescribed tablet growth remained strong at 70% year over year*
SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2015. Total revenues for the fourth quarter were $14.1 million compared to $7.1 million for the same period in 2014. Net loss for the fourth quarter was $13.4 million compared to a net loss of $17.7 million for the fourth quarter of 2014. At December 31, 2015, XenoPort had... More
